Protein / target

Cell adhesion molecule CEACAM5

Encoded byCEACAM5P06731Homo sapiensSwiss-Prot

UniProt: P06731 Ensembl: ENSG00000105388 HGNC: HGNC:1817 NCBI Gene: 1048

Clinically validated

Therapeutic maturity

Approved medicines

Open Targets target-level

Small-molecule tractable

Druggability

Structure with Ligand

Research papers

Protein at a glance

Biological role

Protein homodimerization

Strongest disease association

Dementia

Via encoding gene CEACAM5 · Genetic evidence · score 0.23

Therapeutic position

Established drug target

Antibodies

Research activity

Emerging research

1 papers · latest 2020

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression.

View complete UniProt function annotation

Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling and tumor progression (PubMed:10864933, PubMed:10910050, PubMed:2803308). Mediates homophilic and heterophilic cell adhesion with other carcinoembryonic antigen-related cell adhesion molecules, such as CEACAM6 (PubMed:2803308). Plays a role as an oncogene by promoting tumor progression; induces resistance to anoikis of colorectal carcinoma cells (PubMed:10910050)

Subcellular location

Cell membraneApical cell membraneCell surface

Domains and Gene Ontology detail (25)

Domains & features

Ig-like V-typeIg-like C2-type 1Ig-like C2-type 2Ig-like C2-type 3Ig-like C2-type 4Ig-like C2-type 5Ig-like C2-type 6

Gene Ontology

Capical plasma membrane
Cbasolateral plasma membrane
Ccell surface
Cextracellular exosome
Cextracellular region
Cmembrane
Cplasma membrane
Cside of membrane
FGPI anchor binding
Fidentical protein binding
Fprotein homodimerization activity
Papoptotic process

702 aa · 77 kDa · 2 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Oncogenic signallingUniProtCell adhesionUniProt · GOApoptosis & cell deathGO

View supporting evidence

Oncogenic signalling

·Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling an…

Cell adhesion

·Cell surface glycoprotein that plays a role in cell adhesion, intracellular signaling an…
·heterophilic cell-cell adhesion
·homophilic cell-cell adhesion
·homotypic cell-cell adhesion

Apoptosis & cell death

·apoptotic process
·negative regulation of apoptotic process

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene CEACAM5

Gene-level evidence surfaced through the gene CEACAM5 that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Carcinoma, Non-Small-Cell Lung

0.56Moderately supported

Clinical evidence dominant · Open Targets 0.40

Colorectal Neoplasms

0.48Limited support

Clinical evidence dominant · Open Targets 0.38

Neurodegenerative Diseases

0.30Preliminary

Pathway evidence dominant · Open Targets 0.45 · no direct causal or clinical evidence

Gonorrhea

0.28Preliminary

Pathway evidence dominant · Open Targets 0.38 · no direct causal or clinical evidence

Dementia

0.25Preliminary

Genetic evidence dominant · Open Targets 0.15

View evidence synthesis (5)

Carcinoma, Non-Small-Cell LungModerately supported

0.56

agreement 0.42–0.69

Clinical69%Literature22%RNA expression9%

Open Targets aggregate 0.40 · 3 independent evidence families

Colorectal NeoplasmsLimited support

0.48

agreement 0.33–0.64

Clinical90%Literature10%

Open Targets aggregate 0.38 · 2 independent evidence families

Neurodegenerative DiseasesPreliminary

0.30

agreement 0.12–0.48

Pathway98%Literature2%

Open Targets aggregate 0.45 · 2 independent evidence families · no direct causal or clinical evidence

GonorrheaPreliminary

0.28

agreement 0.10–0.46

Pathway84%Literature16%

Open Targets aggregate 0.38 · 2 independent evidence families · no direct causal or clinical evidence

DementiaPreliminary

0.25

agreement 0.11–0.39

Genetic94%Literature6%

Open Targets aggregate 0.15 · 2 independent evidence families

This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations

Neurodegenerative Diseases0.45

Carcinoma, Non-Small-Cell Lung0.40

Colorectal Neoplasms0.38

Gonorrhea0.38

Autoimmune disorder of central nervous system0.22

Dementia0.15

Drug development

5 compounds recorded · 1 approved · 4 in clinical development

Open Targets' development universe — every compound recorded against the target at any stage, not all approved medicines.

View all recorded compounds (5)

ARCITUMOMABApproval

LABETUZUMABPhase 2

LABETUZUMAB GOVITECANPhase 2

MEDI-565Phase 1

TUSAMITAMAB RAVTANSINEPhase 3

Open Targets known-drugs universe. Drug name and highest clinical stage only — the disease relationship is NOT read from this slice (it carries trial-context noise); approved indications come from the canonical graph above.

Tractability

Small molecules — Emerging

Feasibility evidence (structure with ligand) — no clinical-stage drug of this modality recorded.

Antibodies — Strong

Approved Drug and UniProt loc high conf support this modality.

Other modalities — Strong

Advanced Clinical support this modality.

View underlying tractability evidence (7)

SM · Structure with LigandAB · Approved DrugAB · UniProt loc high confAB · GO CC high confAB · UniProt SigP or TMHMMAB · Human Protein Atlas locOC · Advanced Clinical

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2020

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Rectal Cancer.228 cites

You YN · Diseases of the colon and rectum · 2020

Recent

The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Rectal Cancer.

You YN · Diseases of the colon and rectum · 2020

Europe PMC papers linked directly to this protein.